raloxifene hydrochloride - Profile

What are the generic sources for raloxifene hydrochloride and what is the scope of freedom to operate?

Raloxifene hydrochloride is the generic ingredient in two branded drugs marketed by Lilly, Amneal Pharms, Aurobindo Pharma, Cadila Pharms Ltd, Glenmark Pharms Ltd, Invagen Pharms, Sciegen Pharms, Teva Pharms Usa, and Watson Labs Inc, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.

Summary for raloxifene hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	9
NDAs:	9

US Patents and Regulatory Information for raloxifene hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997	AB	RX	Yes	Yes
Amneal Pharms	RALOXIFENE HYDROCHLORIDE	raloxifene hydrochloride	TABLET;ORAL	208206-001	Apr 8, 2016	AB	RX	No	No
Aurobindo Pharma	RALOXIFENE HYDROCHLORIDE	raloxifene hydrochloride	TABLET;ORAL	204310-001	Aug 28, 2015	AB	RX	No	No
Cadila Pharms Ltd	RALOXIFENE HYDROCHLORIDE	raloxifene hydrochloride	TABLET;ORAL	211324-001	Aug 18, 2020	AB	RX	No	No

Expired US Patents for raloxifene hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997
Lilly	EVISTA	raloxifene hydrochloride	TABLET;ORAL	020815-001	Dec 9, 1997

Raloxifene Hydrochloride Investment Scenario and Patent Fundamentals (Orange Book, Exclusivity, Generics Risk, and Commercial Outlook)

Last updated: July 30, 2026

Raloxifene hydrochloride is an established, small-molecule SERM with mature global supply and long-exhausted product-brand exclusivity in most markets. From an IP-investment perspective, the core opportunity is not blocking first-time generic entry, but identifying (1) remaining patent-protected formulation/manufacturing improvements, (2) method-of-use claims that may still be active in select jurisdictions, and (3) any ongoing legal or regulatory events that create near-term IP leverage. Commercially, the investment case hinges on whether a sponsor is pursuing a differentiated line extension (new dosage form, dosing regimen, combination, or bioequivalent-compatible process) and whether it can win share versus entrenched generics.

What patents protect raloxifene hydrochloride, and who holds the estate?

Featured snippet: For raloxifene hydrochloride, the active patent estate is generally not centered on the original drug substance in major markets; it is typically fragmented across formulation/process and secondary indications, with many foundational claims already expired. Any investable leverage normally comes from remaining secondary patents that still cover specific dosage forms, manufacturing methods, or new therapeutic uses.

Drug substance vs. product patents: what to expect

Most long-lived enforcement for older oral SERMs concentrates in:

• Formulation patents: tablet composition, excipient system, dissolution profile, particle size or polymorph selection.
• Manufacturing/process patents: granulation method, compression/handling parameters, impurity control.
• Method-of-use patents: a specific indication, patient subgroup, dosing schedule, or combination therapy.

Likely patent holder landscape (assignee typology)

Raloxifene’s earliest discovery and development are historically associated with major pharma innovators in endocrine and osteoporosis categories. In today’s market, patent enforcement and licensing is often handled by:

• The original developer’s assignees, if any later-life patents remain.
• Smaller firms or local rightsholders with reformulation portfolios.
• Generic entrants with negotiated carve-outs where settlements occur.

Practical IP diligence checklist for investors

For a credible investment thesis, diligence should map:

• Every active claim family covering (a) raloxifene hydrochloride tablet formulations, (b) process steps, (c) specific dosing regimens, and (d) any method-of-use beyond osteoporosis.
• Jurisdiction-by-jurisdiction status since enforcement and expiration differ by country and patent term adjustments.
• Claim-to-product mapping: which generic labels actually practice the protected features (e.g., specific dissolution specification or impurity profile).

When does raloxifene lose exclusivity, and what timelines matter for generic entry risk?

Featured snippet: Raloxifene hydrochloride is past primary brand exclusivity in most regulated markets; near-term generic entry risk is usually driven by whether a sponsor has remaining secondary patents that a potential entrant can or cannot design around.

US regulatory exclusivity: what investors should anchor to

For oral small molecules, generic entry is primarily a function of:

• Patent expiration (listed in the US Orange Book for the specific NDA and strength),
• Any relevant regulatory exclusivities (rare in long-mature products in practice),
• Whether there are blocking patents tied to the specific dosage form and strength.

Patent term and “last to expire” logic

For investment planning, focus on:

• Earliest expiration for each claim family (to model generic design-around feasibility),
• Last-to-expire for each dosage form/strength (to model timelines for any potential challenge or court decision),
• Family dispersion: a formulation patent in one strength can be a bottleneck even if other strengths are free to enter.

How to time an investment decision

The investable window is usually:

• Before launch of a generic with a risk-optimized Paragraph IV strategy,
• Between settlement and launch for branded holders trying to maximize remaining protected shelf space,
• During ongoing litigation if a court decision could clarify claim scope and unblock design options for future entrants.

How strong is the patent estate for raloxifene hydrochloride?

Featured snippet: In mature SERMs like raloxifene, “strength” is usually limited to remaining formulation/process or narrow method-of-use claims. A strong estate is one that is (1) still active, (2) clearly tied to marketed dosage forms, and (3) difficult to design around without losing bioequivalence.

Patent strength indicators investors should score

• Claim breadth: broad composition or specific excipient/processing constraints.
• Evidence of enforcement: actual Paragraph IV litigations or injunction outcomes in the past decade.
• Design-around feasibility: whether alternatives can be developed while staying within generic bioequivalence specs.
• Litigation track record: whether courts have repeatedly narrowed similar claims in other SERMs.

Formulation patent strength versus process patents

• Formulation patents can be strong if they lock in specific excipient systems or physicochemical properties that are not interchangeable.
• Process patents can be weak if a generic manufacturer can switch manufacturing steps and still meet impurity and dissolution specs.

What is the Orange Book status of raloxifene hydrochloride?

Featured snippet: Raloxifene hydrochloride is widely available as generic product in the US. Orange Book listings for active blocking patents, if any exist at present, are the key gating items for new generic launches.

What to extract from Orange Book for investment modeling

For each NDA product and strength, map:

• Patent numbers,
• Patent expiry dates (and any pediatric term adjustments),
• Patent type (drug substance, drug product, method of use),
• Whether exclusivity is tied to a specific formulation.

Orange Book-to-commercial translation

• Blocking patents that track to marketed strengths can delay generic competition.
• If patents are not listed for a particular strength, or are expired, generic entry risk is materially higher.

What formulations are protected by raloxifene hydrochloride patents?

Featured snippet: Protected “formulations” for raloxifene typically mean tablet composition and/or controlled dissolution and impurity profiles, not broad coverage of raloxifene itself.

Dosage form coverage that often drives disputes

• Oral tablets (most market-relevant),
• Any line extensions (e.g., alternative strengths),
• Any combination product formulations if pursued.

What generic entrants typically change to design around

• Excipient selection within acceptable pharmacopeial ranges,
• Granulation method and compression parameters,
• Particle size distribution and dissolution modifiers.

Investability criterion

A formulation patent is investable only if:

• It is active,
• It covers a commercially used strength,
• It constrains critical quality attributes such that design-around threatens bioequivalence or increases manufacturing cost materially.

What method-of-use patents cover raloxifene hydrochloride?

Featured snippet: Method-of-use claims are usually narrow for older SERMs, and many are exhausted or non-blocking for generic competition unless tied to an active patent listed to the approved NDA.

Method-of-use risk framing

Method-of-use patents can matter if:

• They define a specific clinical use not already covered by current labeling,
• They remain active and are listed as blocking patents for the relevant NDA.

How this impacts investment

• If no active method-of-use patents remain, a strategy that relies on litigation-based exclusivity is weak.
• If active claims remain, the business case depends on whether future generic labels could be “carved” from claimed uses or whether off-label prescribing creates infringement risk in practice.

Which companies are challenging raloxifene hydrochloride with Paragraph IV ANDA filings?

Featured snippet: For mature products like raloxifene, Paragraph IV filings tend to occur only when there is a still-active patent wall. Investment relevance comes from identifying current-wave filers tied to remaining listed patents.

How to evaluate challenger behavior

• Whether challengers target drug product patents or method-of-use patents,
• Whether they file for all strengths or only some,
• Whether litigation is ongoing or settled, and whether settlements show a “trigger date” tied to patent expiry.

What an investor should model

• Expected launch date range,
• Design-around pace,
• Settlement scope: market entry carve-outs, injunction/escrow-like terms, or agreed launch dates.

What patent litigation affects raloxifene hydrochloride?

Featured snippet: The investment signal is whether there is active US patent litigation tied to Orange Book-listed patents that could block (or delay) generic entry of a specific dosage form.

Litigation types that change the cash-flow outlook

• Court rulings narrowing or invalidating active patents,
• Settlements that allow generic launch after a defined date,
• Stipulations that limit scope and reduce injunction leverage.

What investors should map in litigation

• Case numbers and jurisdictions,
• Asserted patents and expiration dates,
• Relief sought: injunction, declaratory judgment, or damages,
• Settlement terms that create predictable launch timing.

What settlements were reached for raloxifene hydrochloride, and how do they change market timing?

Featured snippet: Settlements matter because they establish launch calendars even when patents expire later or are contested.

Timing mechanics that drive value

• “Launch-to-expiration” bridges: settlement-triggered entry dates can be earlier than full patent expiration.
• Strength-specific agreements: only certain doses may be permitted at first entry.
• Carve-outs for label changes: may allow entry without committing to a method-of-use claim.

How does raloxifene hydrochloride perform commercially, and what revenue exposure matters for investors?

Featured snippet: Raloxifene is a mature generic-dominant product class in most markets; revenue growth opportunities typically come from share gains in specific regions, differentiation via line extensions, or new clinical programs. Pure IP leverage on the original product is usually not the driver.

Key commercial drivers investors should model

• Generic price compression and channel stocking behavior,
• Regulatory accessibility and manufacturing scale,
• Prescriber and guideline dynamics in osteoporosis prevention and treatment,
• Replacement risk from other SERMs and endocrine therapies.

Revenue exposure framework for a rights-holder

• Identify whether the investor exposure is tied to a still-sold branded product or to royalty streams from licensing.
• Model share erosion after generic entry and expected time-to-full substitution.

How does raloxifene compare with other SERMs and osteoporosis therapies?

Featured snippet: In osteoporosis and breast cancer risk reduction portfolios, raloxifene competes against other SERMs and a broader category of anti-resorptive agents and endocrine therapies with different efficacy and safety profiles.

Competitive adjacency investors should assess

• Other SERMs (e.g., tamoxifen, bazedoxifene): different indication mix and label restrictions.
• Bisphosphonates and denosumab: different risk-benefit and administration.
• Newer endocrine and estrogen-pathway agents: they may shift treatment patterns over time.

What matters for investment

• Market share is less about patent protection and more about formulary positioning, safety profile differentiation, and payer contracting.
• A differentiated raloxifene product must offer measurable advantages: dosing convenience, tolerability, or pharmacokinetic improvements that translate into clinical or economic benefit.

What generic entry risks exist for raloxifene hydrochloride?

Featured snippet: Generic entry risk is high where no active blocking patents remain for the relevant NDA and strength, and low only where remaining active patent walls map tightly to marketed product features.

Risk scenarios investors should score

• Low risk: active patents exist but are not tied to marketed strengths, or claims are narrow and easily designed around.
• Medium risk: active formulation/process patents exist but are likely to be invalidated or settled.
• High risk: active patents exist and challengers have filed, signaling strong likelihood of near-term entry unless litigation blocks it.

How does the drug’s manufacturing and IP landscape affect barriers to entry?

Featured snippet: For established oral small molecules, the main barriers are formulation know-how and impurity control, not fundamental chemical synthesis.

Manufacturing/IP constraints that can slow generic launch

• Specific polymorph or particle-size handling requirements,
• Tight impurity specifications requiring controlled process windows,
• Proprietary dissolution or stability targets used to justify equivalence.

Investor implication

If a sponsor owns manufacturing know-how tied to active patents, the business case can be stronger than a purely legal thesis. If the patents are expired or narrow and easily bypassed, generic entry barriers fall quickly.

Key Takeaways

• Raloxifene hydrochloride is a mature, generic-dominant product class; the investable IP thesis typically rests on remaining secondary patent families covering specific formulations, processes, or narrow method-of-use claims.
• Generic entry timing is determined by Orange Book-listed blocking patents tied to specific NDA strengths, with settlements and ongoing litigation serving as primary near-term schedule drivers.
• Commercial upside is more likely to come from line extensions and differentiation than from blocking first-time generic penetration.
• The highest-value diligence work is mapping remaining active patents to marketed strengths and determining design-around feasibility for likely ANDA entrants.

FAQs

1) Which Orange Book patents typically block generic raloxifene tablets?
Drug product patents (formulation/composition or specific dissolution/quality attributes) are most likely to be blocking when still active; method-of-use patents matter only if they are listed as blocking for the NDA and strength.

2) Do formulation patents matter more than process patents for raloxifene generics?
Formulation patents usually drive product equivalence risk more directly because they can constrain excipient systems or physicochemical profiles; process patents can be easier to design around.

3) How do label carve-outs and settlement agreements affect raloxifene generic launch dates?
Settlements can fix a launch calendar and may require label modifications that avoid practicing asserted method-of-use claims, reducing infringement exposure.

4) What indicators show a strong remaining patent wall for raloxifene?
Active patents with enforceable claim scope tied to the commercially sold strength and evidence of litigation focus (frequent reassertion or Paragraph IV challenges) are strongest indicators.

5) What commercial metrics should be used to size an investment in a raloxifene franchise?
Brand residue vs generic share, expected price erosion after entry, payer/formulary placement stability, and royalty/licensing terms tied to remaining patent estates.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. FDA. Approved Drug Products: Raloxifene Hydrochloride (search in Orange Book and associated labeling). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
3. FDA. ANDA and Paragraph IV guidance and statutory framework for patent challenges. U.S. Food and Drug Administration. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
4. United States Patent and Trademark Office (USPTO). Patent term and exclusivity concepts. USPTO. https://www.uspto.gov/